Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)
Aug 02 2018
Mar 13 2020
The purpose of this Funding Opportunity Announcement (FOA) is to support the discovery of promising candidate biomarkers that will facilitate the development of non-opioid therapeutic options for the treatment of pain conditions. The goal of this FOA is to encourage a biomarker discovery process that will result in the development of pain biomarkers that can withstand rigorous clinical and analytical validation. It is hoped that an increased availability of rigorous biomarkers for pain will facilitate the discovery and development of transformational non-opioid therapeutics for pain.